Annexon Biosciences Q3 Loss Narrows as Cash Runway Extends to 2028
Annexon Biosciences reported a narrower third-quarter net loss, citing lower research and development expenses, and said its cash runway extends to 2028.
Story updates
09:21:17 PM UTC
SquawkNews
Annexon reported a third-quarter 2026 net loss attributable to common stockholders of $51.2 million, or $0.25 per share, compared with $54.9 million, or $0.37 per share, a year earlier. Cash, cash equivalents and short-term investments totaled $213.4 million at September 30, 2026, with the company…
OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using…